Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 9/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12034638 | 0.93 | KCNH2 (0.80) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL50194 | 0.91 | KCNH2 (0.79) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL12034632 | 0.91 | KCNH2 (0.79) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13818564 | 0.90 | KCNH2 (0.78) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL13791867 | 0.90 | KCNH2 (0.62) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL12619942 | 0.89 | KCNH2 (0.58) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL19316504 | 0.89 | KCNH2 (0.58) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL12619973 | 0.89 | KCNH2 (0.58) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| SCHEMBL3930658 | 0.89 | KCNH2 (0.58) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 | |
| Trifluoroacetic Acid SCHEMBL50161 | 0.89 | KCNH2 (0.74) | KCNH2NR1I2CYP3A4SCN5ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2518073-B1 | Compounds for the treatment of Hepatitis C | BRISTOL MYERS SQUIBB CO (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20140186299-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140186299-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140045816-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130171098-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130171098-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-07-04 | — | — | US | disclosed |
| US-20120115847-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-10 | — | — | US | disclosed |
| US-8129367-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129367-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110311480-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-22 | — | — | US | disclosed |
| US-20090162318-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-06-25 | — | — | US | disclosed |
| US-20090162318-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-06-25 | — | — | US | disclosed |
| US-20090130057-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-21 | — | — | US | disclosed |
| US-20090130057-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2009-05-21 | — | — | US | disclosed |
| US-7521443-B2 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521443-B2 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-21 | — | — | US | disclosed |
| US-20080146537-A1 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-19 | — | — | US | disclosed |
| US-20080146537-A1 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311480-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | KCNH2 2019/4885NR1I2 298/4885CYP3A4 54/4885 |
| US-20140045816-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | KCNH2 2019/4885NR1I2 298/4885CYP3A4 54/4885 |
| US-20120115847-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | KCNH2 3808/4885NR1I2 189/4885CYP3A4 214/4885 |
| US-20080146537-A1 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | ZC3HAV1, ODC1, MED1 | KCNH2 1814/4885NR1I2 343/4885CYP3A4 2107/4885 |
| US-20140186299-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | KCNH2 2019/4885NR1I2 298/4885CYP3A4 54/4885 |
| US-20090130057-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | KCNH2 3808/4885NR1I2 189/4885CYP3A4 214/4885 |
| US-20090162318-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | KCNH2 2019/4885NR1I2 298/4885CYP3A4 54/4885 |
| US-20130171098-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | KCNH2 2019/4885NR1I2 298/4885CYP3A4 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.